KMT2A and acute leukemia: Therefore, targeting DOT1L [13, 18, 19] represents an attractive therapeutic option for patients diagnosed with KMT2A-rearranged acute leukemia, despite the first-in-class DOT1L inhibitor pinometostat showing dissatisfying results in adult patients [15].